Fisher, Luminex to Develop Molecular Dx Products
 
Fisher HealthCare, a division of Thermo Fisher Scientific, and Luminex will use Luminex’s xMAP instruments and assays to jointly identify molecular diagnostic applications, Luminex said last week.  
 
Luminex, which develop and manufacture resulting products, said that by granting Fisher the US rights to its xMAP technology it gains a sales avenue through Fisher’s sales teams, its “access to key clinical accounts,” and its “extensive logistics network.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.